Vivos Inc. Takes a Major Step with IDE Application Submission

Author: Dylan Bailey Updated: 07-14-2025 08:34 AM

Vivos Inc. Submits IDE Application for RadioGel

Kennewick, WA – Vivos Inc. (OTCQB: RDGL) has recently unveiled a major advancement in its commitment to revolutionize cancer care. The company announced the submission of its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel, an innovative hydrogel-based radioactive therapy aimed at targeting solid tumors.

Understanding the Significance of the IDE Submission

This submission to the FDA is a pivotal moment for Vivos Inc. It carries with it extensive data derived from both animal and human studies, paving the way for what the company hopes will be a significant breakthrough in cancer treatments. With RadioGel, Vivos aims to deliver precise radiation directly to tumors, thus significantly reducing the collateral damage to adjacent healthy tissues, a challenge that has long plagued traditional cancer therapies.

The development of the IDE application was not a solitary endeavor; it resulted from months of collaboration with the FDA under the Breakthrough Device program. This initiative is designed to accelerate the approval process for medical devices that address serious or life-threatening conditions. Through this pathway, the company has sought to alleviate concerns regarding the safety and efficacy of RadioGel, bolstering its submission with a robust compilation of evidence.

Leadership’s Vision for the Future of Cancer Treatment

Dr. Michael Korenko, the CEO of Vivos Inc., expressed his enthusiasm regarding the application, stating, "This is our most comprehensive IDE submission to date, backed by both animal and human data. The constructive discussions we had with the FDA were instrumental in shaping this submission, and they underscore our commitment to delivering transformative therapies to those in need of cancer treatments."

What Sets RadioGel Apart?

RadioGel stands out in the realm of cancer therapies because of its innovative approach to radiation delivery. Traditional therapies often result in collateral damage to healthy tissues; however, RadioGel is designed to minimize this risk, which could lead to a better quality of life for patients undergoing treatment. These qualities make RadioGel a promising solution in the ongoing battle against cancer.

The Next Steps for Vivos Inc.

As Vivos Inc. awaits feedback from the FDA on its IDE application, the company remains focused on advancing its mission to introduce effective new therapies to the market. This is not merely about gaining regulatory approval; it's about changing the landscape of cancer treatment to offer more hope and better outcomes for patients facing tough battles against tumors.

Interested parties can reach out directly to Vivos Inc. through its CEO, Dr. Michael Korenko, via email at MKorenko@RadioGel.com.

Frequently Asked Questions

What is the aim of Vivos Inc.'s IDE application?

Vivos Inc. aims to gain FDA approval for RadioGel, a new cancer treatment that delivers targeted radiation to solid tumors.

What is RadioGel?

RadioGel is a hydrogel-based radioactive therapy designed to minimize damage to surrounding healthy tissue while targeting tumors.

How does this IDE submission impact cancer treatment?

This submission represents a significant advancement by offering a potential new treatment option that uses precision delivery of radiation.

Who is leading Vivos Inc.?

Dr. Michael Korenko serves as the President and CEO of Vivos Inc. and is a driving force behind the company’s innovations.

How can I follow updates from Vivos Inc.?

You can follow Vivos Inc. on X (Twitter) under the handle @VivosIncUSA for the latest insights and updates.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.